Rigel(RIGL) - 2025 Q2 - Earnings Call Presentation

1 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, continued development and expansion of our business, projected financial performance including sales and revenue growth, continued advancement of our R289 study, future Phase 2 studies of olutasidenib in recurrent glioma, potential identification of opportunities and completion of acquisition or in-license of ...